References for Treatment Report Home



References for Treatment Report

1. Institute of Medicine. Gulf War Veterans: Treating Symptoms and Syndromes. Committee on Identifying Effective Treatments for Gulf War Veterans' Health Problems. Editors Bernard M. Rosof and Lyla M. Hernandez. Washington, D.C.: National Academy Press; 2001:152.

2. Moher D, Reviews. DotTCCCfS, Assistant CHoEORIa, Professor of the Department of Pediatrics at the University of Ottawa. Does the inclusion of grey literature influence the estimates of intervention effectiveness reported in meta-analyses? [abstract]. Research Seminar Series, UCLA Division of General Internal Medicine/Health Services Research and the Clinical Scholars Program. June 2000. Los Angeles; 2000.

3. Collins JF, Donta ST, Engel CC, et al. The antibiotic treatment trial of Gulf War Veterans' Illnesses: issues, design, screening, and baseline characteristics. Control Clin Trials. 2002;23:333-53.

4. Hilborne L, Golomb B. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 1: Infectious Diseases. Washington, DC: RAND; 1998.

5. Hyman ES. Urinary sediment examination and Gulf War Syndrome. Am J Med Sci. 1998;316:411-3.

6. Nicolson GL, Nicolson NL. Diagnosis and treatment of mycoplasma infections. ; 1995.

7. Nicolson GL, Nicolson NL. The isolation, purification, and analysis of specific gene-containing nucleoproteins and nucleoprotein complexes. Methods Mol Genetics. 1994;5:281-298.

8. Rea WJ, Pan Y, Johnson AR, Ross GH, Suyama H, Fenyves EJ. Reduction of chemical sensitivity by means of heat depuration, physical therapy and nutritional supplementation in a controlled environment. J Nutritional Medicine. 1996;6.

9. Kilburn KH, Warsaw RH, Shields MG. Neurobehavioral dysfunction in firemen exposed to polycholorinated biphenyls (PCBs): possible improvement after detoxification. Arch Environ Health. 1989;44:345-50.

10. Folkers K, Nilsson JL. [Coenzyme Q regarded as a vitamin]. Nord Med. 1970;83:489-93.

11. Bargossi AM, Battino M, Gaddi A, et al. Exogenous CoQ10 preserves plasma ubiquinone levels in patients treated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Int J Clin Lab Res. 1994;24:171-6.

12. England JD, Walsh JC, Stewart P, Boyd I, Rohan A, Halmagyi GM. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin [letter]. Australian and New Zealand Journal of Medicine. 1995;25:374-5.

13. Barbiroli B, Frassineti C, Martinelli P, et al. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cellular and Molecular Biology. 1997;43:741-9.

14. Chen RS, Huang CC, Chu NS. Coenzyme Q10 treatment in mitochondrial encephalomyopathies. Short-term double-blind, crossover study. European Neurology. 1997;37:212-8.

15. Folkers K, Simonsen R. Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta. 1995;1271:281-6.

16. Kuz'menko IV, Donchenko GV, Kovalenko VN, Gololobov AD, Tarasova NV. [Efficiency of ubiquinone and p-oxybenzoic acid in prevention of E-hypovitaminosis-induced development of muscular dystrophy]. Ukr Biokhim Zh. 1981;53:73-9.

17. Shimomura Y, Suzuki M, Sugiyama S, Hanaki Y, Ozawa T. Protective effect of coenzyme Q10 on exercise-induced muscular injury. Biochem Biophys Res Commun. 1991;176:349-55.

18. Kamikawa T, Kobayashi A, Yamashita T, Hayashi H, Yamazaki N. Effects of coenzyme Q10 on exercise tolerance in chronic stable angina pectoris. Am J Cardiol. 1985;56:247-51.

19. Alleva R, Tomasetti M, Andera L, et al. Coenzyme Q blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. FEBS Lett. 2001;503:46-50.

20. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology. 2001;57:515-8.

21. Fernandez-Ayala DJ, Martin SF, Barroso MP, et al. Coenzyme Q protects cells against serum withdrawal-induced apoptosis by inhibition of ceramide release and caspase-3 activation. Antioxid Redox Signal. 2000;2:263-75.

22. Kagan T, Davis C, Lin L, Zakeri Z. Coenzyme Q10 can in some circumstances block apoptosis, and this effect is mediated through mitochondria. Ann N Y Acad Sci. 1999;887:31-47.

23. Mosca L, Marcellini S, Perluigi M, et al. Modulation of apoptosis and improved redox metabolism with the use of a new antioxidant formula. Biochem Pharmacol. 2002;63:1305-14.

24. Schults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease. Evidence of slowing of the functional decline. Archives of Neurology. 2002;59:1541-50.

25. Haley RW, Marshall WW, McDonald GG, Daugherty MA, Petty F, Fleckenstein JL. Brain abnormalities in Gulf War syndrome: Evaluation with 1H MR spectroscopy. Radiology. 2000;215:807-817.

26. Sinzinger H, Schmid P, O'Grady J. Two different types of exercise-induced muscle pain without myopathy and CK -elevation during HMG-Co-enzyme-A-reductase inhibitor treatment. Atherosclerosis. 1999;143:459-460.

27. Muller DP, Lloyd JK, Wolff OH. Vitamin E and neurological function: abetalipoproteinaemia and other disorders of fat absorption. Ciba Found Symp. 1983;101:106-21.

28. Muller DPR, Lloyd JK, Bird A. Long-term management of abetalipoproteinemia. Possible role for vitamin E. Arch Dis Child. 1977;52:209-14.

29. Iannaccone ST, Sokol RJ. Vitamin E deficiency in neuropathy of abetalipoproteinemia. Neurology. 1986;36:1009.

30. Hegele RA, Angel A. Arrest of neuropathy and myopathy in abetalipoproteinemia with high-dose vitamin E therapy. Can Med Assoc J. 1985;132:41-4.

31. Azizi E, Zaidman JL, Eschar J, Aszeinberg A. Abetalipoproteinemia treated with parenteral and oral vitamin A and E and with medium chain triglycerides. Acta Pediatr Scand. 1978; 67:797-801.

32. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. Vitamin E and cognitive decline in older persons. Archives of Neurology. 2002;59:1125-1132.

33. Veltkamp R, Toole JF. Hyperbaric oxygen--a neuroprotective adjuvant for hyperacute ischemic stroke? Journal of the Neurological Sciences. 1997;150:1-2.

34. Clifton GL. Hypothermia and hyperbaric oxygen as treatment modalities for severe head injury. New Horizons. 1995;3:474-8.

35. Nighoghossian N, Trouillas P. Hyperbaric oxygen in the treatment of acute ischemic stroke: an unsettled issue. Journal of the Neurological Sciences. 1997;150:27-31.

36. Nighoghossian N, Trouillas P, Adeleine P, Salord F. Hyperbaric oxygen in the treatment of acute ischemic stroke. A double-blind pilot study. Stroke. 1995;26:1369-72.

37. Berrouschot J, Schwab S, Schneider D, Hacke W. [Hyperbaric oxygen therapy (HBO) after acute focal cerebral ischemia]. Nervenarzt. 1998;69:1037-44.

38. Krakovsky M, Rogatsky G, Zarchin N, Mayevsky A. Effect of hyperbaric oxygen therapy on survival after global cerebral ischemia in rats. Surgical Neurology. 1998;49:412-6.

39. Jain. Textbook of Hyperbaric Medicine. ; 1999.

40. . ms/mscenter/index.html. Treating Multiple Sclerosis (MS) with Hyperbaric Oxygen Therapy (HBO). 2000.

41. Heuser G, Uszler JM. Hyperbaric oxygenation for cerebral palsy. Lancet. 2001;357:2053-4.

42. O'Donnell P, Buxton PJ, Pitkin A, Jarvis LJ. The magnetic resonance imaging appearances of the brain in acute carbon monoxide poisoning. Clinical Radiology. 2000;55:273-80.

43. Stuppaeck CH, Miller CH, Ehrmann H, Fleischhacker WW, Felber S, Poewe W. Akathisia induced by necrosis of the basal ganglia after carbon monoxide intoxication. Movement Disorders. 1995;10:229-231.

44. Albin RL. Basal ganglia neurotoxins. Neurologic Clinics,. 2000;18:665-80.

45. Kao CH, Hung DZ, ChangLai SP, Liao KK, Chieng PU. HMPAO brain SPECT in acute carbon monoxide poisoning. Journal of Nuclear Medicine. 1998;39:769-72.

46. Weaver L, Howe S, Hopkins R, Chan KJ. Carboxyhemoglobin half-life in carbon monoxide-poisoned patients treated with 100% oxygen at atmospheric pressure. Chest. 2000;117:801-8.

47. Golomb BA. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 2: Pyridostigmine Bromide. Santa Monica, CA: RAND; 1999:385.

48. Cecchine G, Golomb BA, Hilborne LH, Spektor DM, Anthony CR. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Vol 8: Pesticides. Santa Monica, CA: RAND; 2000:182.

49. Augerson W. A Review of the Scientific Literature as it Pertains to Gulf War Illnesses, Volume 5: Chemical and Biological Warfare Agentsw. Washington, D.C.: RAND; 2000.

50. Nicolson GL, Nicolson NL, Nasralla M. Mycoplasmal infections and fibromyalgia/chronic fatigue illness (Gulf War Illness) associated with deployment to Operation Desert Storm. International Journal of Medicine. 1998;1:80-89.

51. Duerksen S. Infection may hold clue to Gulf ills: Bacteria being found in many ailing vets. San Diego Union Tribune; 2000:B1.

52. Fukuda K, Nisenbaum R, Stewart G, et al. Chronic multisymptom illness affecting Air Force veterans of the Gulf War. Jama. 1998;280:981-8.

53. May KP, West SG, Baker MR, Everett DW. Sleep apnea in male patients with the fibromyalgia syndrome. Am J Med. 1993;94:505-8.

54. Molony RR, MacPeek DM, Schiffman PL, et al. Sleep, sleep apnea and the fibromyalgia syndrome. J Rheumatol. 1986;13:797-800.

55. Alvarez Lario B, Alonso Valdivielso JL, Alegre Lopez J, Martel Soteres C, Viejo Banuelos JL, Maranon Cabello A. Fibromyalgia syndrome: overnight falls in arterial oxygen saturation. Am J Med. 1996;101:54-60.

56. Plantamura A, Steinbauer J, Eisinger J. [Sleep apnea and fibromyalgia: the absence of correlation does not indicate an exclusive central hypothesis]. Rev Med Interne. 1995;16:662-5.

57. Alvarez Lario B, Teran J, Alonso JL, Alegre J, Arroyo I, Viejo JL. Lack of association between fibromyalgia and sleep apnoea syndrome. Ann Rheum Dis. 1992;51:108-11.

58. Jennum P, Drewes AM, Andreasen A, Nielsen KD. Sleep and other symptoms in primary fibromyalgia and in healthy controls. J Rheumatol. 1993;20:1756-9.

59. Harding SM. Sleep in fibromyalgia patients: subjective and objective findings. Am J Med Sci. 1998;315:367-76.

60. Fischler B, Le Bon O, Hoffmann G, Cluydts R, Kaufman L, De Meirleir K. Sleep anomalies in the chronic fatigue syndrome. A comorbidity study. Neuropsychobiology. 1997;35:115-22.

61. Paiva T, Batista A, Martins P, Martins A. The relationship between headaches and sleep disturbances. Headache. 1995;35:590-6.

62. Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr Pharm Biotechnol. 2000;1:11-31.

63. Green D, Lawler M, Rosen M, et al. Recombinant human erythropoietin: effect on the functional performance of anemic orthopedic patients. Arch Phys Med Rehabil. 1996;77:242-6.

64. Ekblom B. Blood doping and erythropoietin. The effects of variation in hemoglobin concentration and other related factors on physical performance. Am J Sports Med. 1996;24:S40-2.

65. Hengemihle JM, Abugo O, Rifkind J, Spangler E, Danon D, Ingram DK. Chronic treatment with human recombinant erythropoietin increases hematocrit and improves water maze performance in mice. Physiol Behav. 1996;59:153-6.

66. Verbrugge DJ, Goodnough LT. The effect of recombinant human erythropoietin treatment on the endurance performance of Sprague-Dawley rats. Scand J Clin Lab Invest. 1994;54:55-9.

67. Martin GR, Ongkingo JR, Turner ME, Skurow ES, Ruley EJ. Recombinant erythropoietin (Epogen) improves cardiac exercise performance in children with end-stage renal disease. Pediatr Nephrol. 1993;7:276-80.

68. McMahon LP, Johns JA, McKenzie A, Austin M, Fowler R, Dawborn JK. Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant. 1992;7:1199-206.

69. Adamson JW, Vapnek D. Recombinant erythropoietin to improve athletic performance. N Engl J Med. 1991;324:698-9.

70. Braumann KM, Nonnast-Daniel B, Boning D, Bocker A, Frei U. Improved physical performance after treatment of renal anemia with recombinant human erythropoietin. Nephron. 1991;58:129-34.

71. Scott WC. The abuse of erythropoietin to enhance athletic performance. Jama. 1990;264:1660.

72. Huppmann M, Hief C, Schenk E, Nurnberg M, Meisl F, Kummer F. [Erythropoietin therapy in renal anemia. Effect on ergospirometry performance parameters]. Wien Med Wochenschr Suppl. 1989;104:suppl 48-50.

73. Bocker A, Reimers E, Nonnast-Daniel B, et al. Effect of erythropoietin treatment on O2 affinity and performance in patients with renal anemia. Contrib Nephrol. 1988;66:165-75.

74. Corey-Bloom J. Ginkgo biloba slows cognitive decline in patients with multiple sclerosis. Annual Meeting of the American Academy of Neurology. Denver, CO; 2002.

75. Joint National Committee. The Sixth Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure (JNC VI). Arch Intern Med. 1997;157:2413-2446.

76. Matsubayashi K, Okumiya K, Wada T, et al. Postural dysregulation in systolic blood pressure is associated with worsened scoring on neurobehavioral function tests and leukoaraiosis in the older elderly living in a community. Stroke. 1997;28:2169-73.

77. Korten AE, Jorm AF, Jiao Z, et al. Health, cognitive, and psychosocial factors as predictors of mortality in an elderly community sample. Journal of Epidemiology and Community Health. 1999;53:83-88.

78. Guo Z, Fratiglioni L, Winblad B, Viitanen M. Blood pressure and performance on the Mini-Mental State Examination in the very old. Cross-sectional and longitudinal data from the Kungsholmen Project. American Journal of Epidemiology. 1997;145:1106-1113.

79. Guo Z, Fratiglioni L, Zhu L, Fastbom J, Winblad B, Viitanen M. Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Archives of Neurology. 1999;56:991-6.

80. Zhu L, Viitanen M, Guo Z, Winblad B, Fratiglioni L. Blood pressure reduction, cardiovascular diseases, and cognitive decline in the mini-mental state examination in a community population of normal very old people: a three-year follow-up. Journal of Clinical Epidemiology. 1998;51:385-01.

81. Guo Z, Viitanen M, Winblad B, Fratiglioni L. Low blood pressure and incidence of dementia in a very old sample: dependent on initial cognition. Journal of the American Geriatrics Society. 1999;47:723-6.

82. Kario K, Motai K, Mitsuhashi T, et al. Autonomic nervous system dysfunction in elderly hypertensive patients with abnormal diurnal blood pressure variation: relation to silent cerebrovascular disease. Hypertension. 1997;30:1504-10.

83. Watanabe N, Imai Y, Nagai K, et al. Nocturnal blood pressure and silent cerebrovascular lesions in elderly Japanese. Stroke. 1996;27:1319-27.

84. Langer RD, Ganiats TG, Barrett-Connor E. Paradoxical survival of elderly men with high blood pressure. Bmj (Clinical Research Ed.). 1989;298:1356-7.

85. Langer RD, Ganiats TG, Barrett-Connor E. Factors associated with paradoxical survival at higher blood pressures in the very old [published erratum appears in Am J Epidemiol 1993 Nov 1;138(9):774]. American Journal of Epidemiology. 1991;134:29-38.

86. Langer RD, Criqui MH, Barrett-Connor EL, Klauber MR, Ganiats TG. Blood pressure change and survival after age 75. Hypertension. 1993;22:551-9.

87. Jancin B. Blood pressure rise reperfuses stroke. Internal Medicine News; 2002:1-2.

88. De Lorenzo F, Hargreaves J, Kakkar VV. Pathogenesis and management of delayed orthostatic hypotension in patients with chronic fatigue syndrome. Clin Auton Res. 1997;7:185-90.

89. Peroutka SJ. Chronic fatigue disorders: an inappropriate response to arginine vasopressin? Med Hypotheses. 1998;50:521-3.

90. Rowe PC, Calkins H, DeBusk K, et al. Fludrocortisone acetate to treat neurally mediated hypotension in chronic fatigue syndrome: a randomized controlled trial. Jama. 2001;285:52-9.

91. Baschetti R. Investigations of hydrocortisone and fludrocortisone in the treatment of chronic fatigue syndrome. J Clin Endocrinol Metab. 1999;84:2263-4.

92. Peterson PK, Pheley A, Schroeppel J, et al. A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med. 1998;158:908-14.

93. Hanelt W. Experience with atropine, 3*.000125g/d for chronic fatigue. Letter to Dr. Golomb dated 2-15-00. 2000.

94. Golomb BA. Illness in Persian Gulf War veterans: Evidence for a causal role for acetylcholinesterase inhibitors (pyridostigmine bromide, pesticides, and nerve agent). Submitted.

95. Rustam H, Von Burg L, Amin-Zaki L, El Hassani S. Evidence for a neuromuscular disorder in methylmercury poisoning. Arch Environ Health. 1975;30:190-195.

96. Braham J. Drop attacks in the elderly: Effect of pyridostigmine. Postgraduate Medical Journal. 1994;70:848.

97. Trojan D, Cashman N. Anticholinesterases in post-poliomyelitis syndrome. Ann NY Acad Sci. 1995;753:285-295.

98. Trojan D, Cashman N. An open trial of pyridostigmine in post-poliomyelitis syndrome. Canadian J of Neurological Sciences. 1995;22:223-227.

99. Park K, Kim D, Arnold TW, Oh SJ, Bradley R. Pyridostigmine toxicity: Electrophysiological study. Electromyogr Clin Neurophysiol. 1993;33:323-328.

100. Jancin B. Blood pressure rise reperfuses stroke. Internal Medicine News; 2002:1-2.

101. Cupler FJ, Otero C, Hench K, Luciano C, Dalakas MC. Acetylcholine receptor antibodies as markers of treatable fatigue in HIV-1 infected individuals. Muscle and Nerve. 1996;19:1186-1188.

102. Robbins TW, McAlonan G, Muir JL, Everitt BJ. Cognitive enhancers in theory and practice: Studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease. Behav Brain Res. 1997;83:15-23.

103. Davis KL, Mohs RC, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS. Physostigmine: improvement of long-term memory processes in normal humans. Science. 1978;201:272-4.

104. Mohs RC, Davis KL, Tinklenberg JR, Pfefferbaum A, Hollister LE, Kopell BS. Cognitive effects of physostigmine and choline chloride in normal subjects. In: Davis K, Berger P, eds. Brain Acetylcholine and Neuropsychiatric Disease. New York: Plenum Press; 1979:237-251.

105. Christie JE, Shering A, Ferguson J, Glen AI. Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry. 1981;138:46-50.

106. Peters B, Levin H. Memory enhancement after physostigmine in the amnesic syndrome. Arch Neurol. 1977;34:215.

107. Mohs R, Davis B, et al. Oral physostigmine treatment of patients with Alzheimer's disease. Am J Psychiatry. 1979;142:28-33.

108. Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav. 1995;51:509-14.

109. Westman EC, Levin ED, Rose JE. Nicotine as a therapeutic drug. N C Med J. 1995;56:48-51.

110. Alagiakrishnan K, Wong W, Blanchette PL. Use of donepezil in elderly patients with Alzheimer's disease--a Hawaii based study. Hawaii Med J. 2000;59:57-9.

111. Burov Iu V, Baimanov TD, Maisov NI. [Effects of amiridin and tacrine, drugs effective in Alzheimer's disease, on synaptosomal uptake of neuromediators]. Biull Eksp Biol Med. 1992;113:379-81.

112. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry. 2001;49:289-99.

113. Cummings JL, Gorman DG, Shapira J. Physostigmine ameliorates the delusions of Alzheimer's disease. Biol Psychiatry. 1993;33:536-41.

114. Fuschillo C, La Pia S, Campana F, Pinto A, De Simone L. Cognitive deficits in Alzheimer's disease: Treatment with acetylcholinesterase inhibitor agents. Arch Gerontol Geriatr. 2001;33 Suppl 1:151-158.

115. Geib SJ, Tuckmantel W, Kozikowski AP. Huperzine A--a potent acetylcholinesterase inhibitor of use in the treatment of Alzheimer's disease. Acta Crystallogr C. 1991;47 ( Pt 4):824-7.

116. Gottwald MD, Rozanski RI. Rivastigmine, a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin Investig Drugs. 1999;8:1673-1682.

117. Lopez-Pousa S, Lombardia Fernandez C. [Treatment of Alzheimer's disease: acetylcholinesterase inhibitors]. Neurologia. 1999;14:180-8.

118. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). Cochrane Database Syst Rev. 2002:CD001747.

119. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med. 1998;158:1021-31.

120. Donnelly-Roberts DL, Puttfarcken PS, Kuntzweiler TA, et al. ABT-594 [(R)-5-(2-Azetidinyl-methoxy)-2-Chloropyridine]: A novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterization. J Pharmacol Exp Ther. 1998;285:777-786.

121. Damaj MI, Creasy KR, Grove AD, Rosecrans JA, Martin BR. Pharmacological effects of epibatidine optical enantiomers. Brain Res. 1994;662:34-40.

122. Damaj MI, Martin BR. Tolerance to the antinociceptive effect of epibatidine after acute and chronic administration in mice. Eur J Pharmacol. 1996;300:51-57.

123. Barlocco D, Cignarella G, Tondi D, et al. Mono- and di-substituted-3,8-Diazabicyclo[3.2.1] octane derivatives as analgesics structurally related to epibatidine: synthesis, activity, and modeling. J Med Chem. 1998;41:674-681.

124. Bannon AW, Gunther KL, Decker MW. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (+/-)-epibatidine. Pharmacol Biochem Behav. 1995;51:693-698.

125. Holladay MW, Wasicak JT, Lin NH, et al. Identification and initial structure-activity relationships of (R)-5-(2-Azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J Med Chem. 1998;41:407-412.

126. Khan IM, Yaksh TL, Taylor P. Epibatidine binding sites and activity in the spinal cord. Brain Res. 1997;753:269-282.

127. Puttfarcken PS, Manelli AM, Arneric SP, Donnelly-Roberts DL. Evidence for nicotinic receptors potentially modulating nociceptive transmission at the level of the primary sensory neuron: Studies with F11 cells. J Neurochem. 1997;69:930-938.

128. Rao TS, Correa LD, Reid RT, Lloyd GK. Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (NAChR) ligands in the rat tail-flick assay. Neuropharmacology. 1996;35:393-405.

129. Rupniak NM, Patel S, Marwood R, et al. Antinociceptive and toxic effects of (+)-epibatidine oxalate attributable to nicotinic agonist activity. Br J Pharmacol. 1994;113:1487-1493.

130. Jurna I, Krauss P, Baldauf J. Depression by nicotine of pain-related nociceptive activity in the rat thalamus and spinal cord. Clin Investig. 1993;72:65-73.

131. Ando Y. Transdermal nicotine for ulcerative colitis [letter]. Ann Intern Med. 1997;127:491-2; discussion 492-3.

132. Baron JA. Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious. Br Med Bull. 1996;52:58-73.

133. Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases? Br J Nurs. 1996;5:1195-202.

134. Bonapace CR, Mays DA. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease. Ann Pharmacother. 1997;31:907-13.

135. Bonner GF. Current medical therapy for inflammatory bowel disease [see comments]. South Med J. 1996;89:556-66.

136. Compton RF, Sandborn WJ, Lawson GM, et al. A dose-ranging pharmacokinetic study of nicotine tartrate following single-dose delayed-release oral and intravenous administration. Aliment Pharmacol Ther. 1997;11:865-74.

137. Finnie IA, Campbell BJ, Taylor BA, et al. Stimulation of colonic mucin synthesis by corticosteroids and nicotine. Clin Sci (Colch). 1996;91:359-64.

138. Green JT, Thomas GA, Rhodes J, et al. Nicotine enemas for active ulcerative colitis--a pilot study. Aliment Pharmacol Ther. 1997;11:859-63.

139. Griffel L, Das KM. Nicotine and ulcerative colitis. Natl Med J India. 1994;7:222-3.

140. Guslandi M, Tittobello A. Pilot trial of nicotine patches as an alternative to corticosteroids in ulcerative colitis. J Gastroenterol. 1996;31:627-9.

141. Guslandi M, Tittobello A. Transdermal nicotine for ulcerative colitis [letter]. Ann Intern Med. 1997;127:492; discussion 492-3.

142. Kennedy LD. Nicotine therapy for ulcerative colitis. Ann Pharmacother. 1996;30:1022-3.

143. Koop I. [Nicotine for ulcerative colitis--a new therapeutic principle?]. Z Gastroenterol. 1994;32:656-7.

144. Paran H, Silverberg D, Mayo A, Shwartz I, Neufeld D, Freund U. Treatment of acute colonic pseudo-obstruction with neostigmine. J Am Coll Surg. 2000;190:315-8.

145. Pierach CA. Neostigmine for acute colonic pseudo-obstruction. N Engl J Med. 1999;341:1622-3.

146. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999;341:137-41.

147. Sarna S, Latimer P, Campbell D, Waterfall WE. Effect of stress, meal and neostigmine on rectosigmoid electrical control activity (ECA) in normals and in irritable bowel syndrome patients. Dig Dis Sci. 1982;27:582-91.

148. St John PH, Radcliffe AG. Contraindication for the use of neostigmine in colonic pseudo-obstruction. Br J Surg. 1997;84:1481-2.

149. Trevisani GT, Hyman NH, Church JM. Neostigmine: safe and effective treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000;43:599-603.

150. Turegano-Fuentes F, Munoz-Jimenez F, Del Valle-Hernandez E, et al. Early resolution of Ogilvie's syndrome with intravenous neostigmine: a simple, effective treatment. Dis Colon Rectum. 1997;40:1353-7.

151. van der Spoel JI, Oudemans-van Straaten HM, Stoutenbeek CP, Bosman RJ, Zandstra DF. Neostigmine resolves critical illness-related colonic ileus in intensive care patients with multiple organ failure--a prospective, double-blind, placebo-controlled trial. Intensive Care Med. 2001;27:822-7.

152. Vavilala MS, Lam AM. Neostigmine for acute colonic pseudo-obstruction. N Engl J Med. 1999;341:1622; discussion 1623.

153. Nicholson D. Neostigmine for acute colonic pseudo-obstruction. N Engl J Med. 1999;341:1623.

154. Loffeld RJ. [Neostigmine for the treatment of acute pseudo-obstruction of the colon (Ogilvie syndrome)]. Ned Tijdschr Geneeskd. 2001;145:1034.

155. Kreis ME, Kasparek M, Zittel TT, Becker HD, Jehle EC. Neostigmine increases postoperative colonic motility in patients undergoing colorectal surgery. Surgery. 2001;130:449-56.

156. Koornstra JJ, Klaver NS, ter Maaten JC, Limburg AJ, van der Jagt EJ, van der Werf TS. [Neostigmine treatment of acute pseudo-obstruction of colon (Ogilvie syndrome)]. Ned Tijdschr Geneeskd. 2001;145:586-9.

157. Hasler WL. Neostigmine for acute colonic pseudo-obstruction: new use for an old drug? Gastroenterology. 2000;118:443-4.

158. Fink S, Chaudhuri TK. Neostigmine treatment for acute colonic pseudo-obstruction. Dis Colon Rectum. 2000;43:1454.

159. Daaboul B, Eaker EY. Successful decompression of colonic pseudo-obstruction with neostigmine. Am J Gastroenterol. 1999;94:3371-2.

160. Cyba-Altunbay S, Bauer J. [Therapy of prolonged postoperative intestinal atony following interventions on the aorto-iliac circulation. Results of a prospective randomized study with ceruletide lyophilysate versus neostigmine]. Fortschr Med. 1985;103:441-4.

161. Breccia M, Girmenia C, Mecarocci S, et al. Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. Ann Hematol. 2001;80:614-6.

162. Amaro R, Rogers AI. Neostigmine infusion: new standard of care for acute colonic pseudo-obstruction? Am J Gastroenterol. 2000;95:304-5.

163. Althausen PL, Gupta MC, Benson DR, Jones DA. The use of neostigmine to treat postoperative ileus in orthopedic spinal patients. J Spinal Disord. 2001;14:541-5.

164. Abeyta BJ, Albrecht RM, Schermer CR. Retrospective study of neostigmine for the treatment of acute colonic pseudo-obstruction. Am Surg. 2001;67:265-8; discussion 268-9.

165. Abbasakoor F, Evans A, Stephenson BM. Neostigmine for acute colonic pseudo-obstruction. N Engl J Med. 1999;341:1622; discussion 1623.

166. Sadjadpour K. Pyridostigmine bromide and constipation in Parkinson's disease. Jama. 1983;249:1148.

167. Yellin AE, Newman J, Donovan AJ. Neostigmine-induced hyperperistalsis. Effects on security of colonic anastomoses. Arch Surg. 1973;106:779-84.

168. Salin-Pascual RJ, de la Fuente JR, Galicia-Polo L, Drucker-Colin R. Effects of transdermal nicotine on mood and sleep in nonsmoking major depressed patients. Psychopharmacology (Berl). 1995;121:476-9.

169. Davis KL, Berger PA, Hollister LE, Defraites E. Physostigmine in mania. Arch Gen Psychiatry. 1978;35:119-22.

170. Khouzam HR, Kissmeyer PM. Physostigmine temporarily and dramatically reversing acute mania. Gen Hosp Psychiatry. 1996;18:203-4.

171. Shopsin B, Janowsky D, Davis J, Gershon S. Rebound phenomena in manic patients following physostigmine. Preliminary observations. Neuropsychobiology. 1975;1:180-7.

172. Hein H, Kirsten D, Jugert C, Magnussen H. [Nicotine as therapy of obstructive sleep apnea?]. Pneumologie. 1995;49 Suppl 1:185-6.

173. Wirth JA. [Organic psychosyndrome and sleep apnea. Transdermal nicotine--a new therapy concept?]. Pneumologie. 1995;49 Suppl 1:183-4.

174. Davila DG, Hurt RD, Offord KP, Harris CD, Shepard JW, Jr. Acute effects of transdermal nicotine on sleep architecture, snoring, and sleep-disordered breathing in nonsmokers. Am J Respir Crit Care Med. 1994;150:469-74.

175. Obermeyer WH, Benca RM. Effects of drugs on sleep. Neurol Clin. 1996;14:827-40.

176. Wilson AL, Langley LK, Monley J, et al. Nicotine patches in Alzheimer's disease: pilot study on learning, memory, and safety. Pharmacol Biochem Behav. 1995;51:509-14.

177. Vazquez J, Guzman-Marin R, Salin-Pascual RJ, Drucker-Colin R. Transdermal nicotine on sleep and PGO spikes. Brain Res. 1996;737:317-20.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download